Skip to main content
CORESTEMCHEMON Inc. logo

CORESTEMCHEMON Inc. — Investor Relations & Filings

Ticker · 166480 ISIN · KR7166480004 KO Professional, scientific and technical activities
Open in API
Filings indexed 274 across all filing types
Latest filing 2025-05-02 Director's Dealing
Country KR South Korea
Listing KO 166480

About CORESTEMCHEMON Inc.

https://www.corestemchemon.com/eng/main…

CORESTEMCHEMON Inc. is a biotechnology company operating through two main divisions: a biopharmaceutical unit and a non-clinical Contract Research Organization (CRO) unit. The biopharmaceutical division is dedicated to the research and development of new drugs based on stem cell therapy technology. Its clinical pipeline primarily targets neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis, as well as autoimmune diseases like systemic lupus erythematosus (SLE) and fibrosis. The non-clinical CRO division provides comprehensive preclinical services, conducting essential toxicity and efficacy evaluations for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices to support regulatory approval processes.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific executive (Kwang Sun Kwon) of Corestemchemone Co., Ltd. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2025-05-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions (share purchases or sales) by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2025-05-02 Korean
투자판단관련주요경영사항 (뉴로나타-알주(자가골수유래중간엽줄기세포) 품목허가사항 변경 허가 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) titled 'Investment Judgment Related Major Management Matters'. It details a specific corporate action: the application for a change in the product approval status for 'Neuronalta-R' (a stem cell therapy) with the Ministry of Food and Drug Safety (MFDS). It provides specific clinical trial results, regulatory submission dates, and links to previous related disclosures. Since this is a formal regulatory announcement of a material corporate event that does not fit into specific categories like financial reports or dividend notices, it is classified as a general regulatory filing.
2025-04-30 Korean
소속부변경
Regulatory Filings Classification · 1% confidence The document is a short regulatory notice regarding a change in the company's market classification (from 'Mid-sized Enterprise' to 'Venture Enterprise') on the stock exchange. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding company status, it falls under the RNS category.
2025-04-30 Korean
교환사채(해외교환사채포함)발행후만기전사채취득 (제3회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Corestemchemone regarding the acquisition of exchangeable bonds before maturity (Put Option exercise). It details the bond series, acquisition amount, date, and the method of acquisition (over-the-counter). This falls under capital structure and financing updates, specifically related to debt management and capital changes, which aligns with the 'CAP' (Capital/Financing Update) category.
2025-04-28 Korean
투자판단관련주요경영사항(임상시험결과) (근위축성측삭경화증(루게릭병) 환자를 대상으로 뉴로나타-알주(자가골수유래중간엽줄기세포)의 유효성 및 안전성 평가를 위한 3상 임상시험결과보고서 최종본(CSR Final) 수령)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Corestemchemone) submitted to the Korea Exchange (KRX). It details the results of a Phase 3 clinical trial for a drug (Neuronata-R). This type of disclosure, which provides specific updates on clinical trial outcomes and regulatory status, is classified as a Regulatory Filing (RNS) within the provided schema, as it serves as a formal corporate announcement of material business information.
2025-04-25 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.